Robeco Institutional Asset Management B.V. Buys 119,786 Shares of Insulet Corporation $PODD

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in Insulet Corporation by 141.4% during the second quarter, acquiring 119,786 shares to bring its total holdings to 204,494 shares valued at approximately $64.2 million.
• Insulet reported strong quarterly earnings with $1.17 earnings per share, surpassing analyst expectations, while revenue grew by 32.9% year-over-year to $649.1 million.
• Wall Street analysts maintain a consensus rating of Moderate Buy for Insulet, with a target price ranging from $350 to $415, reflecting confidence in the company's growth potential.

Robeco Institutional Asset Management B.V. raised its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 141.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 204,494 shares of the medical instruments supplier's stock after purchasing an additional 119,786 shares during the period. Robeco Institutional Asset Management B.V. owned 0.29% of Insulet worth $64,248,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT bought a new stake in Insulet in the first quarter valued at $26,000. Larson Financial Group LLC increased its stake in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. SouthState Corp increased its stake in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Kozak & Associates Inc. bought a new stake in Insulet in the second quarter valued at $32,000. Finally, Ramirez Asset Management Inc. bought a new stake in Insulet in the first quarter valued at $53,000.

Insulet Stock Up 2.0%

Insulet stock opened at $312.21 on Friday. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The stock has a market cap of $21.98 billion, a PE ratio of 94.90, a price-to-earnings-growth ratio of 2.54 and a beta of 1.40. The firm's 50-day simple moving average is $320.96 and its 200 day simple moving average is $298.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same period in the previous year, the company earned $0.55 earnings per share. The firm's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada lifted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Canaccord Genuity Group boosted their target price on shares of Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a research report on Monday. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and a consensus target price of $345.47.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.